NCT02596347View on ClinicalTrials.gov

The Role of JAK2 in Alveolar Macrophages (AM's) in Chronic Beryllium Disease (CBD)

CompletedOBSERVATIONAL
Enrollment

3

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 6, 2019

Study Completion Date

December 6, 2019

Conditions
Chronic Beryllium Disease (CBD)Beryllium Sensitization (BeS)
Interventions
PROCEDURE

Blood draw

We will draw 4 heparin tubes for peripheral blood mononuclear cells (PBMC)

PROCEDURE

bronchoscopy

CBD subjects will undergo a bronchoscopy with lavage. This is the passage of a think flexible tube through the nose into the windpipe then into the bronchial tubes. Sterile saltwater solution is through the flexible tube then immediately removed.

Trial Locations (1)

80206

National Jewish Health, Denver

All Listed Sponsors
lead

National Jewish Health

OTHER

NCT02596347 - The Role of JAK2 in Alveolar Macrophages (AM's) in Chronic Beryllium Disease (CBD) | Biotech Hunter | Biotech Hunter